Free Trial
NASDAQ:MYMD

MyMD Pharmaceuticals 5/15/2023 Earnings Report

MyMD Pharmaceuticals logo
$0.10 -0.01 (-7.42%)
As of 08/1/2025

MyMD Pharmaceuticals EPS Results

Actual EPS
-$1.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

MyMD Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MyMD Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

MyMD Pharmaceuticals Earnings Headlines

China just unlocked Nvidia’s AI chips—what that means for you
Tired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system tracks breaking AI news and shows when to trade.📈 AI-backed. Beginner-friendly. Results proven.
TNFA TNF Pharmaceuticals, Inc.
See More MyMD Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MyMD Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MyMD Pharmaceuticals and other key companies, straight to your email.

About MyMD Pharmaceuticals

MyMD Pharmaceuticals (NASDAQ:MYMD), a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

View MyMD Pharmaceuticals Profile

More Earnings Resources from MarketBeat